Sarah Marouen1, Thomas Barnetche2, Bernard Combe3, Jacques Morel3, Claire I Daïen4. 1. Rheumatology Department, Lapeyronie Hospital and Montpellier University, France. 2. Rheumatology Department, Pellegrin Hospital and Bordeaux 2 University, France. 3. Rheumatology Department, Lapeyronie Hospital and Montpellier University; and Institute of Molecular Genetic, UMR5535, CNRS, Montpellier, France. 4. Rheumatology Department, Lapeyronie Hospital and Montpellier University; and Institute of Molecular Genetic, UMR5535, CNRS, Montpellier, France. c-daien@chu-montpellier.fr.
Abstract
OBJECTIVES: To assess body composition of patients with inflammatory rheumatic disease and the effect of TNF inhibitors on it. METHODS: This was systematic review with meta-analysis of studies consulted on PubMed, Cochrane Library and EMBASE and assessing body composition in patients with rheumatoid arthritis or spondyloarthritis. We compared i) patients with healthy controls and ii) body components before and after TNF inhibitors. RESULTS: Among the 703 articles reviewed, 19 met the inclusion criteria. In patients with rheumatoid arthritis, a significant increase in fat mass (+1.85 kg, p=0.02), adiposity (+3.53%, p<0.00001) and android mass (+1.7 kg, p<0.00001) and a significant decrease in lean mass (-3.03 kg, p=0.01), were observed. In patients with spondyloarthritis, a significant but modest increase in fat mass (+0.69 kg, p=0.03) and a significant decrease in lean mass (-3.74 kg, p=0.03) were observed. Nine studies assessed impact of TNF inhibitors on body composition, with an increase of fat mass in the short and long term in all studies. Data on lean mass were controversial. Two studies found an increase in visceral or android mass under TNF inhibitors. CONCLUSIONS: Patients with inflammatory rheumatic disease have a significant decrease in lean mass and increase in fat mass. The use of TNF inhibitors is associated with a further increase in fat mass including android fat, which could potentially have cardiovascular consequences.
OBJECTIVES: To assess body composition of patients with inflammatory rheumatic disease and the effect of TNF inhibitors on it. METHODS: This was systematic review with meta-analysis of studies consulted on PubMed, Cochrane Library and EMBASE and assessing body composition in patients with rheumatoid arthritis or spondyloarthritis. We compared i) patients with healthy controls and ii) body components before and after TNF inhibitors. RESULTS: Among the 703 articles reviewed, 19 met the inclusion criteria. In patients with rheumatoid arthritis, a significant increase in fat mass (+1.85 kg, p=0.02), adiposity (+3.53%, p<0.00001) and android mass (+1.7 kg, p<0.00001) and a significant decrease in lean mass (-3.03 kg, p=0.01), were observed. In patients with spondyloarthritis, a significant but modest increase in fat mass (+0.69 kg, p=0.03) and a significant decrease in lean mass (-3.74 kg, p=0.03) were observed. Nine studies assessed impact of TNF inhibitors on body composition, with an increase of fat mass in the short and long term in all studies. Data on lean mass were controversial. Two studies found an increase in visceral or android mass under TNF inhibitors. CONCLUSIONS:Patients with inflammatory rheumatic disease have a significant decrease in lean mass and increase in fat mass. The use of TNF inhibitors is associated with a further increase in fat mass including android fat, which could potentially have cardiovascular consequences.
Authors: Mariana Peixoto Guimarães Ubirajara E Silva de Souza; Nathalia Sernizon Guimarães; Maria Fernanda Brandão de Resende Guimarães; Viviane Angelina de Souza; Adriana Maria Kakehasi Journal: Adv Rheumatol Date: 2022-05-23
Authors: Erik Hulander; Helen M Lindqvist; Anna Turesson Wadell; Inger Gjertsson; Anna Winkvist; Linnea Bärebring Journal: Nutrients Date: 2022-03-02 Impact factor: 5.717